{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:17:08Z","timestamp":1791998228078,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503352"],"award-info":[{"award-number":["82503352"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203755"],"award-info":[{"award-number":["82203755"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Training Project of The First Affiliated Hospital of Nanchang University","award":["YFYLCYJPY202444"],"award-info":[{"award-number":["YFYLCYJPY202444"]}]},{"name":"the Science and Technology Project of Health Commission of Jiangxi Provincial","award":["202510240"],"award-info":[{"award-number":["202510240"]}]},{"name":"Natural Science Foundation of Xinjiang Province of China","award":["2023D01C123"],"award-info":[{"award-number":["2023D01C123"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04258-y","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:00:57Z","timestamp":1769490057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and prognostic model development of immune checkpoint inhibitor rechallenge in recurrent or\u00a0metastatic nasopharyngeal carcinoma: a real-world study"],"prefix":"10.1007","volume":"75","author":[{"given":"Yaofei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixin","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"4258_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"10192","author":"Y-P Chen","year":"2019","unstructured":"Chen Y-P, Chan ATC, Le Q-T et al (2019) Nasopharyngeal carcinoma. Lancet 10192:64\u201380","journal-title":"Lancet"},{"key":"4258_CR2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10555-024-10176-9","volume":"3","author":"ZY Su","year":"2024","unstructured":"Su ZY, Siak PY, Lwin YY et al (2024) Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. Cancer Metastasis Rev 3:919\u2013939","journal-title":"Cancer Metastasis Rev"},{"key":"4258_CR3","first-page":"22","volume":"1","author":"R-M Feng","year":"2019","unstructured":"Feng R-M, Zong Y-N, Cao S-M et al (2019) Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond) 1:22","journal-title":"Cancer Commun (Lond)"},{"key":"4258_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.09.006","author":"CM Tsang","year":"2020","unstructured":"Tsang CM, Lui VWY, Bruce JP et al (2020) Translational genomics of nasopharyngeal cancer. Semin Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.006","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"4258_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12935-019-0863-5","volume":"19","author":"Z-L Huang","year":"2019","unstructured":"Huang Z-L, Liu S, Wang G-N et al (2019) The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Cancer Cell Int 19(1):141","journal-title":"Cancer Cell Int"},{"key":"4258_CR6","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","volume":"10054","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S et al (2016) Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 10054:1883\u20131892","journal-title":"Lancet"},{"key":"4258_CR7","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/bjc.2017.357","volume":"12","author":"A Prawira","year":"2017","unstructured":"Prawira A, Oosting SF, Chen TW et al (2017) Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review. Br J Cancer 12:1743\u20131752","journal-title":"Br J Cancer"},{"key":"4258_CR8","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"20","author":"H-Q Mai","year":"2023","unstructured":"Mai H-Q, Chen Q-Y, Chen D et al (2023) Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA 20:1961\u20131970","journal-title":"JAMA"},{"key":"4258_CR9","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","volume":"8","author":"Y Yang","year":"2021","unstructured":"Yang Y, Qu S, Li J et al (2021) Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 8:1162\u20131174","journal-title":"Lancet Oncol"},{"issue":"6","key":"4258_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","volume":"41","author":"Y Yang","year":"2023","unstructured":"Yang Y, Pan J, Wang H et al (2023) Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell 41(6):1061\u20131072","journal-title":"Cancer Cell"},{"key":"4258_CR11","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1158\/1078-0432.CCR-21-0822","volume":"23","author":"C Even","year":"2021","unstructured":"Even C, Wang H-M, Li S-H et al (2021) Phase II, randomized study of spartalizumab (PDR001), an anti-PD-1 antibody, versus chemotherapy in patients with recurrent\/metastatic nasopharyngeal cancer. Clin Cancer Res 23:6413\u20136423","journal-title":"Clin Cancer Res"},{"key":"4258_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","volume":"3","author":"ATC Chan","year":"2023","unstructured":"Chan ATC, Lee VHF, Hong RL et al (2023) Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann Oncol 3:251\u2013261","journal-title":"Ann Oncol"},{"key":"4258_CR13","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/s41598-024-52034-2","volume":"1","author":"J Feng","year":"2024","unstructured":"Feng J, Chen X, Wei J et al (2024) Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study. Sci Rep 1:2315","journal-title":"Sci Rep"},{"key":"4258_CR14","doi-asserted-by":"publisher","first-page":"943","DOI":"10.7150\/jca.104380","volume":"3","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhang J, He J et al (2025) Efficacy and safety of immune checkpoint inhibitor rechallenge in the treatment of esophageal squamous cell cancer. J Cancer 3:943\u2013951","journal-title":"J Cancer"},{"key":"4258_CR15","doi-asserted-by":"publisher","first-page":"2423479","DOI":"10.1080\/21645515.2024.2423479","volume":"1","author":"M Guo","year":"2024","unstructured":"Guo M, Zhao W, Chen Y et al (2024) Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study. Hum Vaccin Immunother 1:2423479","journal-title":"Hum Vaccin Immunother"},{"key":"4258_CR16","doi-asserted-by":"publisher","first-page":"e2428526","DOI":"10.1001\/jamanetworkopen.2024.28526","volume":"8","author":"L Sun","year":"2024","unstructured":"Sun L, Cohen RB, D\u2019Avella CA et al (2024) Overall survival, treatment duration, and rechallenge outcomes with ICI therapy for recurrent or metastatic HNSCC. JAMA Netw Open 8:e2428526","journal-title":"JAMA Netw Open"},{"key":"4258_CR17","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S460716","author":"W Bei","year":"2024","unstructured":"Bei W, Dong S, Liu G et al (2024) Efficacy and safety of re-challenging PD-1 inhibitors in second-line treatment in metastatic nasopharyngeal carcinoma previously treated with chemotherapy and PD-1 inhibitors. Cancer Manag Res. https:\/\/doi.org\/10.2147\/CMAR.S460716","journal-title":"Cancer Manag Res"},{"key":"4258_CR18","doi-asserted-by":"crossref","unstructured":"Kwon M, Kim G, Kim R, et al (2022) Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J Immunother Cancer 7.","DOI":"10.1136\/jitc-2022-005041"},{"key":"4258_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"4","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 4:375\u2013384","journal-title":"Lancet Oncol"},{"key":"4258_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107355","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Ma Y, Fan Y et al (2023) A multicenter, open-label phase Ib\/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107355","journal-title":"Lung Cancer"},{"key":"4258_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00280-018-3585-9","volume":"6","author":"K Fujita","year":"2018","unstructured":"Fujita K, Uchida N, Kanai O et al (2018) Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Cancer Chemother Pharmacol 6:1105\u20131109","journal-title":"Cancer Chemother Pharmacol"},{"key":"4258_CR22","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/jjco\/hyz066","volume":"8","author":"H Watanabe","year":"2019","unstructured":"Watanabe H, Kubo T, Ninomiya K et al (2019) The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Jpn J Clin Oncol 8:762\u2013765","journal-title":"Jpn J Clin Oncol"},{"key":"4258_CR23","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1186\/s12885-025-14209-6","volume":"1","author":"X Chen","year":"2025","unstructured":"Chen X, Wang K, Liao Y et al (2025) Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis. BMC Cancer 1:862","journal-title":"BMC Cancer"},{"key":"4258_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104113","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Fang T, Lu N et al (2023) Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent\/metastatic nasopharyngeal carcinoma patients. Crit Rev Oncol Hematol. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104113","journal-title":"Crit Rev Oncol Hematol"},{"key":"4258_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12916-025-03985-4","volume":"1","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Bei W, Wang L et al (2025) Efficacy and safety of cadonilimab (PD-1\/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial. BMC Med 1:152","journal-title":"BMC Med"},{"key":"4258_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102043","author":"X Ding","year":"2023","unstructured":"Ding X, Hua Y-J, Zou X et al (2023) Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study. EClinicalMedicine. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102043","journal-title":"EClinicalMedicine"},{"key":"4258_CR27","doi-asserted-by":"publisher","first-page":"4893","DOI":"10.1038\/s41467-023-40402-x","volume":"1","author":"L Yuan","year":"2023","unstructured":"Yuan L, Jia G-D, Lv X-F et al (2023) Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent\/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial. Nat Commun 1:4893","journal-title":"Nat Commun"},{"key":"4258_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.06.005","author":"A Bernard-Tessier","year":"2018","unstructured":"Bernard-Tessier A, Baldini C, Martin P et al (2018) Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2018.06.005","journal-title":"Eur J Cancer"},{"key":"4258_CR29","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/j.jtho.2019.10.012","volume":"1","author":"S Hirano","year":"2020","unstructured":"Hirano S, Hayama N, Tabeta H et al (2020) Drastic Response of Rechallenge of Nivolumab in a Patient with NSCLC Who Progressed on the First Nivolumab Treatment. J Thorac Oncol 1:e20\u2013e22","journal-title":"J Thorac Oncol"},{"key":"4258_CR30","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00280-019-03926-y","volume":"4","author":"A Mouri","year":"2019","unstructured":"Mouri A, Kaira K, Yamaguchi O et al (2019) Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. Cancer Chemother Pharmacol 4:873\u2013880","journal-title":"Cancer Chemother Pharmacol"},{"key":"4258_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217241","author":"X Gang","year":"2024","unstructured":"Gang X, Yan J, Li X et al (2024) Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: current evidence and future directions. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2024.217241","journal-title":"Cancer Lett"},{"key":"4258_CR32","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1016\/j.cllc.2020.04.013","volume":"5","author":"E Gobbini","year":"2020","unstructured":"Gobbini E, Toffart AC, P\u00e9rol M et al (2020) Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients. Clin Lung Cancer 5:e497\u2013e510","journal-title":"Clin Lung Cancer"},{"key":"4258_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.pulmoe.2020.01.007","volume":"4","author":"S Espa\u00f1a","year":"2020","unstructured":"Espa\u00f1a S, Guasch I, Carcereny E (2020) Immunotherapy rechallenge in patients with non-small-cell lung cancer. Pulmonology 4:252\u2013254","journal-title":"Pulmonology"},{"key":"4258_CR34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/1759-7714.15209","volume":"5","author":"G Lin","year":"2024","unstructured":"Lin G, Wang Z, Chu Q et al (2024) Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thorac Cancer 5:419\u2013426","journal-title":"Thorac Cancer"},{"key":"4258_CR35","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.21037\/tlcr-21-682","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Wei L, Li J et al (2021) Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer. Transl Lung Cancer Res 12:4368\u20134379","journal-title":"Transl Lung Cancer Res"},{"key":"4258_CR36","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","volume":"11","author":"J Fucikova","year":"2020","unstructured":"Fucikova J, Kepp O, Kasikova L et al (2020) Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis 11:1013","journal-title":"Cell Death Dis"},{"issue":"9","key":"4258_CR37","doi-asserted-by":"publisher","first-page":"e007474","DOI":"10.1136\/jitc-2023-007474","volume":"11","author":"WJ Jin","year":"2023","unstructured":"Jin WJ, Zangl LM, Hyun M et al (2023) ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models. J Immunother Cancer 11(9):e007474","journal-title":"J Immunother Cancer"},{"key":"4258_CR38","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s43018-023-00600-4","volume":"9","author":"EC Lerner","year":"2023","unstructured":"Lerner EC, Woroniecka KI, D\u2019Anniballe VM et al (2023) CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis. Nat Cancer 9:1258\u20131272","journal-title":"Nat Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04258-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04258-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04258-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:01:00Z","timestamp":1769490060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04258-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4258"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04258-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Research approval was obtained from the Ethics Committee of the Sun Yat-Sen University Cancer Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients had provided informed consent for the participants in the study and publication of any associated data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"47"}}